Holen Sie sich die Stockscreener-App
3.14
9.22%
0.265
Handel nachbörslich:
3.14
Anteris Technologies Global Corp Aktie (AVR) Neueste Nachrichten
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target By Investing.com - Investing.com India
Anteris Technologies Announces Cessation of Securities - TipRanks
Anteris Technologies Announces New Securities Quotation - TipRanks
NanoVibronix (NASDAQ:NAOV) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Review - Defense World
Anteris Technologies Reports March 2025 CDI Adjustments - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV By Investing.com - Investing.com Canada
Anteris reports over 100 patients treated with new heart valve By Investing.com - Investing.com South Africa
Anteris Technologies Hits Milestone with DurAVR® Heart Valve Treatment - Zenopa
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewswire
Anteris reports over 100 patients treated with new heart valve - Investing.com
Anteris Technologies announces 100 patients treated with DurAVR THV - TipRanks
Anteris Technologies Achieves Key Milestone in Cardiac Care - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV - Investing.com
Anteris Technologies Achieves Milestone with DurAVR® Heart Valve - TipRanks
Anteris Technologies marks clinical milestone with more than 100 patients treated using flagship DurAVR® THV - Proactive financial news
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq - MSN
Head to Head Survey: Anteris Technologies Global (NASDAQ:AVR) & United Health Products (OTCMKTS:UEEC) - Defense World
Anteris Technologies reports one-year patient outcomes for DurAVR THV - TipRanks
Anteris shares rise on positive valve trial results By Investing.com - Investing.com Canada
Anteris Reports One-Year Patient Outcomes for DurAVR® THV - The Manila Times
Anteris shares rise on positive valve trial results - Investing.com India
Anteris Technologies Unveils Positive DurAVR® Patient Outcomes - TipRanks
Anteris Technologies delivers strong one-year results for DurAVR® Transcatheter Heart Valve - Proactive financial news
Analyzing Anteris Technologies Global (NASDAQ:AVR) & CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Anteris Technologies Global (NASDAQ:AVR) Stock Price Down 6.2% – What’s Next? - Defense World
Anteris Technologies: Advancing Toward FDA Approval with Positive Buy Rating - TipRanks
Anteris Technologies reports annual financial results By Investing.com - Investing.com South Africa
Anteris Technologies reports annual financial results - Investing.com India
Anteris Reports 2024 Financial Results and Provides Corporate Update - The Manila Times
Anteris Technologies: A Trailblazing Year of Innovation and Expansion - Kondor EXP
The morning catch up: ASX to reverse losses despite war of words over tariffs - Proactive financial news
Anteris Technologies: A Transformational Leap with Its Nasdaq Debut and Heart Valve Breakthroughs - Kondor EXP
Anteris Technologies 2024 financials strong following Nasdaq debut, with plans for heart valve pivotal trial this year - Proactive Investors USA
Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience. - Proactive Investors Australia
Anteris Technologies Reports 2024 Financial Results and Advances Heart Valve Innovations - TipRanks
Anteris Technologies Reports Increased Losses Amid Strategic Reorganization - TipRanks
Anteris Technologies Global Corp. (AVR) reports earnings - Quartz
Small cap wrap: Ocean Power Technologies, Zero Candida, Liberty Star Minerals... - Proactive Investors UK
Anteris Technologies Issues New Shares to Bolster Financial Position - TipRanks
Anteris Technologies appoints David St Denis as President and Class II director - Proactive financial news
3.50%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):